Eli Lilly company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
In newly reported Q1 2026 updates, Eli Lilly showed sharply higher revenue and raised guidance, while Novo Nordisk posted an adjusted sales decline on a constant-currency basis, underscoring a widening gap in the pace of obesity-drug growth between the two leaders.
THE APEX TIMES
THE APEX TIMES
A recent equity note covering Eli Lilly’s stock did not move the benchmark price targets, according to Yahoo Finance, keeping investors focused on what could shift expectations next.
THE APEX TIMES
Eli Lilly’s shares were pulled into renewed debate about long-term growth and dividend appeal after Jefferies raised its price target for the company, pointing to full clinical data for retatrutide.
THE APEX TIMES
Eli Lilly reported positive early clinical data for Foundayo, an oral GLP-1 weight-loss medicine candidate, highlighting efficacy across stages of menopause and different dosing groups in the company’s Triumph-1 study.
THE APEX TIMES
The approval lets eligible patients use a single EBGLYSS (lebrikizumab-lbkz) injection on an eight-week maintenance schedule, reducing the number of injections per year compared with more frequent regimens.
THE APEX TIMES
Eli Lilly has entered a collaboration and licensing agreement with AlzeCure Pharma covering global rights to Alzstatin ACD680, a preclinical treatment candidate for Alzheimer’s disease, according to a new report. The companies said the agreement includes potential payments tied to development milestones and other factors, though specific terms were not detailed in the posting.
THE APEX TIMES
A fresh market call from 24/7 Wall St. puts Eli Lilly stock on track for a move higher over the next year, citing retatrutide Phase 3 attention, a recent earnings beat, and a rebound from earlier pricing and program-related worries.
THE APEX TIMES
The company is adding another early-stage bet in neuroscience by partnering with Swedish biotech AlzeCure Pharma, indicating continued focus on Alzheimer’s disease research even as later-stage programs face clinical and regulatory uncertainty.
THE APEX TIMES
Market coverage points to fresh late-stage results for Lilly’s obesity and diabetes pipeline, helping lift Eli Lilly’s stock to new all-time levels.
